These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 18032969)

  • 1. Antiangiogenic therapy for cancer: an update.
    Shojaei F; Ferrara N
    Cancer J; 2007; 13(6):345-8. PubMed ID: 18032969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Targeting angiogenesis in oncology].
    Fayette J; Soria JC; Armand JP
    Pathol Biol (Paris); 2006 May; 54(4):199-205. PubMed ID: 16753494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic therapy and surgical practice.
    John AR; Bramhall SR; Eggo MC
    Br J Surg; 2008 Mar; 95(3):281-93. PubMed ID: 18278790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.
    Crawford Y; Ferrara N
    Trends Pharmacol Sci; 2009 Dec; 30(12):624-30. PubMed ID: 19836845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of radiation therapy and antiangiogenic therapy.
    O'Reilly MS
    Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
    Cao Y
    Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again?
    Hlushchuk R; Makanya AN; Djonov V
    Int J Dev Biol; 2011; 55(4-5):563-7. PubMed ID: 21858777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance.
    Cao Y; Zhong W; Sun Y
    Semin Cancer Biol; 2009 Oct; 19(5):338-43. PubMed ID: 19481151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
    Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
    Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current strategies and future directions of antiangiogenic tumor therapy.
    Zhang ZL; Wang JH; Liu XY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):873-80. PubMed ID: 14515202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use].
    Plavetić ND; Letilović T; Vrbanec D
    Lijec Vjesn; 2003; 125(9-10):260-5. PubMed ID: 15038217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
    Crawford Y; Ferrara N
    Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of angiogenesis inhibitors in tumour treatment.
    Fayette J; Soria JC; Armand JP
    Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic therapy for primary and metastatic brain tumors.
    Purow B; Fine HA
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1161-81, x. PubMed ID: 15474340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on lymphangiogenesis and angiogenesis in cancer.
    Holopainen T; Bry M; Alitalo K; Saaristo A
    J Surg Oncol; 2011 May; 103(6):484-8. PubMed ID: 21480240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenesis to treat cancer and intraocular neovascular disorders.
    Shojaei F; Ferrara N
    Lab Invest; 2007 Mar; 87(3):227-30. PubMed ID: 17259997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
    Gagne P; Akalu A; Brooks PC
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
    van Heeckeren WJ; Ortiz J; Cooney MM; Remick SC
    J Clin Oncol; 2007 Jul; 25(21):2993-5. PubMed ID: 17634476
    [No Abstract]   [Full Text] [Related]  

  • 20. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
    Ellis LM; Hicklin DJ
    Clin Cancer Res; 2008 Oct; 14(20):6371-5. PubMed ID: 18927275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.